Stage 4 Cancer Smashed – Mayo’s Bold Play

Doctor holding stethoscope with pink ribbon in front
Photo: vectorfusionart / Shutterstock

A Minnesota farmer walked out of a failed cancer fight and into medical history, after doctors turned his own blood cells into a weapon against stage 4 lymphoma.

Quick Take

  • John Renze had stage 4 large B-cell lymphoma that resisted chemotherapy, radiation, and clinical studies for two years
  • He received CAR-T cell therapy at Mayo Clinic in 2016 through one of the first multicenter trials for this cancer
  • His first scan after treatment came back completely clear within weeks
  • He remains in remission today, working full time, farming, and off all medication

A Decade-Old Trial Becomes a Lifeline

Doctors diagnosed Renze with stage 4 large B-cell lymphoma, an aggressive blood cancer. Over two years, he tried chemotherapy, radiation, and several clinical studies. None of it worked. “Nothing got rid of it,” Renze said, describing a disease that kept coming back no matter what treatment he tried.

In 2016, Mayo Clinic enrolled Renze in one of the first multicenter clinical trials testing CAR-T cell therapy for large B-cell lymphoma. Most patients in that trial, like Renze, had stage 3 or 4 disease that had already failed other treatments. The therapy worked by removing a patient’s own T cells, engineering them to hunt cancer, and infusing them back into the body.

From Piles of Cancer to None in Four Weeks

The results came fast. Renze’s first scan after the infusion showed no sign of cancer at all. “I went from piles of cancer to none in four weeks,” he said, describing a turnaround few patients with his history of treatment failure ever see. Independent reporting backed up the timeline, noting his modified T cells were returned to him in July 2016, and by late August, the cancer had vanished.

Dr. Jonas Paludo, a Mayo Clinic hematologist who treated Renze, confirmed the outcome has held. “He doesn’t require any medications,” Paludo said. Renze went back to his normal life, running his farm, working full time, and spending time with his kids and grandkids. Mayo now describes him as one of the longest-living success stories from its early CAR-T program.

Why One Scan Isn’t the Whole Story

Renze’s result lines up with real improvements CAR-T has brought to a disease that once offered grim odds. Before CAR-T, complete response rates in large B-cell lymphoma sat around 7%. After CAR-T, Mayo reports that number climbed to roughly 40% to 54%. That shift explains why Renze’s case drew attention beyond his own farm.

A clear scan is still not the same as a lifetime guarantee, and doctors measure that difference carefully. A large real-world study of 1,159 patients treated with a similar CAR-T product found 44.5% achieved complete response, but only 28.4% stayed cancer-free at two years and 43.6% were alive at that mark. Those numbers show why individual stories and population-wide outcomes tell different parts of the same story.

Renze’s case does not erase that gap. It sits on the favorable side of it. He was treated nearly a decade ago, and his doctors say he remains cancer-free without medication today. For a patient who had run out of options after chemotherapy, radiation, and multiple studies, that outcome speaks for itself. His story also shows why Mayo Clinic continues pointing new patients toward clinical trials when standard treatments stop working, since the same research pipeline that helped Renze keeps expanding CAR-T to more blood cancers every year.

Sources:

youtube.com, x.com, startribune.com, nejm.org